Puberty blocker trial will help reduce harm, says Cass report author

• The Cass Review author supports conducting a puberty blocker trial as essential evidence-gathering, arguing that withholding research poses greater risk to children than the trial itself.
• Dr Hilary Cass emphasises the current evidence gap regarding puberty blockers' long-term effects, indicating this trial is necessary to inform safer clinical practice.
• The trial is framed as harm-reduction strategy, suggesting clinicians currently lack adequate data to optimise treatment decisions for gender-questioning youth.

Dr Hilary Cass says she is "absolutely convinced that more children will be harmed if we don't do the trial than if we do."

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.